Cost Is an Adherence Barrier — Here's How to Address It

If you prescribe Flovent (Fluticasone Propionate) for asthma management, you already know the clinical value of inhaled corticosteroids. But clinical value doesn't matter if your patient can't afford the medication. Medication cost remains one of the leading causes of non-adherence in asthma care, and patients don't always tell you when they're struggling to pay.

This guide covers the practical savings programs, generic options, and conversation strategies that can help your patients stay on therapy.

What Patients Are Paying

Understanding the current pricing landscape helps you guide patients effectively:

• Brand-name Flovent HFA — Discontinued by GSK in January 2024. No longer available.
• Authorized generic Fluticasone Propionate HFA — Cash price ranges from $50–$150 depending on strength (44 mcg, 110 mcg, 220 mcg) and pharmacy.
• With insurance — Most plans cover the authorized generic on Tier 2–3 with copays of $10–$50. Prior authorization may be required for higher strengths. Step therapy protocols sometimes mandate trialing a lower strength first.
• Uninsured or underinsured patients — These patients bear the full cash price and are most at risk for non-adherence or rationing doses.

The transition from brand to authorized generic actually lowered costs for many patients. However, the shift also disrupted coverage for some Medicaid patients whose plans had specific brand-name Flovent coverage agreements. For background, see our provider's guide to the Flovent shortage.

Manufacturer Savings Programs

GSK discontinued brand-name Flovent and does not currently offer savings cards for the authorized generic Fluticasone Propionate HFA. However, several avenues remain:

• Authorized generic manufacturer programs — Some manufacturers of the authorized generic may offer copay assistance or discount programs. Check the manufacturer listed on the patient's specific inhaler for current offerings.
• GSK Patient Assistance Program (GSK For You) — While this program may cover other GSK products for eligible uninsured or underinsured patients, it does not apply to the discontinued Flovent brand. Direct eligible patients to gskforyou.com for their other GSK medications.
• NeedyMeds and RxAssist — These databases catalog available patient assistance programs for Fluticasone Propionate inhalers and can be useful for identifying current options for uninsured patients.

Coupon and Discount Cards

Prescription discount cards can significantly reduce out-of-pocket costs for patients, especially those who are uninsured or whose insurance copay exceeds the discount price:

• GoodRx — Frequently offers Fluticasone Propionate HFA inhalers at discounted prices. Patients can compare pricing across pharmacies in their area.
• SingleCare — Another widely accepted discount card with competitive pricing on generic inhalers.
• RxSaver, BuzzRx, Optum Perks — Additional discount card options that may offer varying prices depending on the pharmacy.

An important clinical note: discount cards cannot be combined with insurance copays. Patients should compare their insurance copay with the discount card price and use whichever is lower. Some patients are surprised to find the discount card price is actually less than their insurance copay.

For a comprehensive patient-facing guide to these options, direct patients to our Flovent savings guide.

Generic Alternatives and Therapeutic Substitution

If cost remains a barrier even with the authorized generic, consider therapeutic alternatives:

• Budesonide (Pulmicort Flexhaler / generic) — Generic budesonide DPI is widely available and may be less expensive on some formularies. Also available as a nebulizer suspension (Pulmicort Respules) for young children.
• Beclomethasone (QVAR RediHaler) — Breath-actuated MDI. May be preferred for patients with coordination difficulties. Check formulary placement.
• Mometasone (Asmanex Twisthaler / generic) — DPI with once-daily dosing option for mild-to-moderate asthma, which may improve adherence.
• Ciclesonide (Alvesco) — Prodrug activated in the lungs. May have fewer local side effects (oral thrush, dysphonia). Worth considering for patients who've had issues with Fluticasone side effects.

When switching, ensure equivalent dosing. A low-dose Fluticasone Propionate regimen (88–264 mcg/day) is roughly equivalent to low-dose Budesonide (180–540 mcg/day) or low-dose Beclomethasone (80–240 mcg/day) based on NAEPP guidelines.

Also consider combination inhalers if the patient requires both ICS and LABA therapy. In some cases, a single combination inhaler (e.g., generic Fluticasone/Salmeterol) may be more cost-effective than prescribing both components separately.

Building Cost Conversations into Your Workflow

Many patients won't volunteer that cost is a problem. Build cost screening into your standard workflow:

At Prescribing

• Ask directly: "Do you have any concerns about the cost of this medication?" Simple, non-judgmental, and effective.
• Check formulary status before prescribing when possible. E-prescribing systems often display formulary information and suggest covered alternatives.
• Prescribe generics by default. Write for "Fluticasone Propionate HFA" rather than "Flovent" (though this is now moot since the brand is discontinued).
• Document the strength rationale. If you're prescribing a higher strength that requires prior authorization, document the clinical justification upfront to streamline the PA process.

At Follow-Up

• Ask about adherence with cost in mind: "Have you been able to fill and use your inhaler as prescribed?" Patients who are rationing doses or skipping refills may have underlying cost concerns.
• Monitor refill patterns. If a patient's refill schedule suggests they're stretching their inhaler beyond 30 days, explore why.
• Offer pharmacy alternatives. Direct patients to Medfinder for Providers to help locate in-stock pharmacies with competitive pricing.

Workflow Integration

• Keep a quick-reference list of current discount card websites and patient assistance program contacts that clinical staff can hand to patients.
• Train front-desk and MA staff to ask about medication cost barriers during intake.
• Use EHR alerts for high-cost medications to prompt cost conversations automatically.

Final Thoughts

Medication adherence in asthma is directly linked to outcomes — and cost is one of the most modifiable barriers. By proactively discussing affordability, steering patients toward generics and discount programs, and keeping therapeutic alternatives in your toolkit, you can help more patients stay on effective inhaled corticosteroid therapy. For pharmacy stock-checking and pricing tools for your practice, visit Medfinder for Providers.